ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

5 links0 made here, not in the record9 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07572123Evaluating the Addition ofMaintenance ImmunotherapyCompared to the UsualTreatment of Chemotherapyand Autologous Stem CellTransplant Alone forHigh-risk Patients WithNational Cancer Institute (NCIPhase 2/Phase 3 · not yet recrRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Version of 2026-11-18CONDITIONSHodgkin DiseaseNo longer in the registry's filing›As of now · Rule based · Main conditionMain conditionDRUGSBrentuximab VedotinIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedINT010169Entry “High Dose Chemotherapy”, read …›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · TestedComparatorNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Brentuximab Vedotin

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Brentuximab Vedotin”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Tested
Tested · 1
Background · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2Brentuximab VedotinClaude Opus 5.5TestedCurrent
Nov 2INT010169Claude Opus 5.5ComparatorCurrent
Nov 2NivolumabClaude Opus 5.5TestedCurrent
Nov 2PembrolizumabClaude Opus 5.5TestedCurrent
Nov 18The record itselfClinicalTrials.gov recordVersion of 2026-11-18Record change
Nov 18Brentuximab VedotinRule based · role ruleBackgroundOverridden
Nov 18INT010169Rule based · role ruleTestedOverridden
Nov 18NivolumabRule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundOverridden
As of nowHodgkin DiseaseRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.